Finanzen von Aurora Cannabis Inc. (ACB)ACBAurora Cannabis Inc.

Aurora Cannabis Inc. (ACB) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Cannabis, accounting for 87.2% of total sales, equivalent to CAD 78.81M. Another important revenue stream is Plant propagation. Understanding this composition is critical for investors evaluating how ACB navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Aurora Cannabis Inc. maintains a gross margin of -5.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.86%, while the net margin is -5.97%. These profitability ratios, combined with a Return on Equity (ROE) of -7.09%, provide a clear picture of how effectively ACB converts its operational activities into shareholder value.

In the context of the broader market, ACB competes directly with industry leaders such as MGPI and VITL. With a market capitalization of $252.61M, it holds a significant position in the sector. When comparing efficiency, ACB's gross margin of -5.95% stands against MGPI's 37.37% and VITL's 6.58%. Such benchmarking helps identify whether Aurora Cannabis Inc. is trading at a premium or discount relative to its financial performance.

Aurora's financial performance shows volatility, with recent quarters reflecting a mix of positive and negative net income, including a net loss of 56.9 million CAD in the last quarter and a gross margin of 47.68% in Q4 2026, which is a positive sign despite overall losses.